Reports Q2 revenue $113.5M, one estimate $107.24M. Q2 adjusted EBITDA $78.3M vs. $78.1M last year. Q2 charter coverage of 87% for the next 12 months based on current operating revenues and 77% in terms of contracted operating days.
HIGHER: Acceleron Pharma (XLRN) up 11.0% after positive Phase 3 data for Luspatercept... Turtle Beach (HEAR) up 2.9% after Buy initiation at DA Davidson... Stitch Fix (SFIX) up 2.5% after Overweight initiation at KeyBanc... Weight Watchers (WTW) up 0.8% after Overweight initiation at KeyBanc... Fossil Group (FOSL) up 0.7% after Overweight initiation at KeyBanc. LOWER: Cactus (WHD) down 5.8% after equity offering... Danaos Corp (DAC) down 4.0% after equity offering... Depomed (DEPO) down 3.7% after disclosing patent settlement discussions with Purdue Pharma... TG Therapeutics (TGTX) down 1.8% after equity offering.
Danaos assumed with a Hold at Jefferies. Jefferies analyst Randy Giveans assumed coverage of Danaos with a Hold rating and $3 price target. The analyst assumed coverage of 23 energy maritime shipping names saying the industry is "primed for significant improvement." For the first time in 10 years, the analyst expects capacity shortages with demand growth to outpace supply growth in every shipping sector in 2018.